With 0.48 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.53 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.1400 whereas the lowest price it dropped to was $1.1000. The 52-week range on GMDA shows that it touched its highest point at $2.62 and its lowest point at $0.56 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.53.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GMDA was down-trending over the past week, with a drop of -8.06%, but this was down by -8.06% over a month. Three-month performance dropped to -41.84% while six-month performance fell -26.45%. The stock lost -55.29% in the past year, while it has lost -11.63% so far this year. A look at the trailing 12-month EPS for GMDA yields -1.18 with Next year EPS estimates of -0.52. For the next quarter, that number is -0.17. This implies an EPS growth rate of 17.90% for this year and 40.20% for next year.
Float and Shares Shorts:
At present, 102.92 million GMDA shares are outstanding with a float of 99.49 million shares on hand for trading. On Aug 30, 2023, short shares totaled 5.02 million, which was 4.13% higher than short shares on Jul 30, 2023. In addition to Ms. Abigail L. Jenkins as the firm’s Pres, CEO & Director, Ms. Michele Ilene Korfin M.B.A., R.Ph. serves as its Chief Operating & Chief Commercial Officer.
Through their ownership of 30.76% of GMDA’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.85% of GMDA, in contrast to 6.74% held by mutual funds. Shares owned by individuals account for 15.34%. As the largest shareholder in GMDA with 6.77% of the stake, Fidelity Management & Research Co holds 8,226,101 shares worth 8,226,101. A second-largest stockholder of GMDA, Stonepine Capital Management LLC, holds 6,854,158 shares, controlling over 5.64% of the firm’s shares. Meitav Mutual Funds Ltd. is the third largest shareholder in GMDA, holding 3,655,158 shares or 3.01% stake. With a 2.32% stake in GMDA, the Fidelity VIP – Growth Portfolio is the largest stakeholder. A total of 2,824,068 shares are owned by the mutual fund manager. The Fidelity Capital Appreciation Fun, which owns about 1.79% of GMDA stock, is the second-largest Mutual Fund holder. It holds 2,169,053 shares valued at 2.56 million. Fidelity Advisor Series I – Equit holds 1.56% of the stake in GMDA, owning 1,895,116 shares worth 2.24 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, GMDA reported revenue of $0.00 and operating income of -$18.05M. The EBITDA in the recently reported quarter was -$17.93M and diluted EPS was -$0.31.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GMDA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With GMDA analysts setting a high price target of $11.00 and a low target of $5.00, the average target price over the next 12 months is $7.00. Based on these targets, GMDA could surge 864.91% to reach the target high and rise by 338.6% to reach the target low. Reaching the average price target will result in a growth of 514.04% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded GMDA stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 4,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 25 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 874,853 while 0 shares were sold.